TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03302195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Based on patient body weight (UI/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Based on patient body weight (UI/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Based on patient body weight (UI/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Based on patient body weight (UI/kg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cardiopulmonary bypass pump flow rate
Description: Based on patient body weight (L/min/m2)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiopulmonary bypass pump flow rate
Description: Based on patient body weight (L/min/m2)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiopulmonary bypass pump flow rate
Description: Based on patient body weight (L/min/m2)
Study: NCT01734694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Dose optimized vancomycin. Target trough: 15 - 20 mg/L for Health Care Associated Pneumonia, Osteomyelitis, Septic Arthritis, Endocarditis and Bacteremia;~Target trough: 10 - 20 mg/L for Acute Bacterial Skin and Skin Structure Infections;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftaroline
Description: Dose based on package insert labeling~CrCL \> 50 mL/min: 600 mg IV q12h~CrCL 31-50 mL/min: 400 mg q12h~CrCL 15-30 mL/min: 300 mg q12h~CrCL \< 15mL/min: 200 mg q12h;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Description: Dose based on renal function and literature dosing recommendations~CrCL ≥ 30 mL/min: 6 - 10 mg/kg IV q24h~CrCL \< 30 mL/min: 6 - 10 mg/kg IV q48h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: 600 mg IV/PO q12h
Study: NCT03302195

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiopulmonary bypass pump flow rate
Description: Based on patient body weight (L/min/m2)
Study: NCT03061383

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 8% Arginine based toothpaste
Description: toothpaste

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 8% strontium acetate based toothpaste
Description: toothpaste

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: toothpaste
Study: NCT04406194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAVICOVIR 200 mg Film Tablet
Description: FAVICOVIR 200 MG FT is containing 200 mg favipiravir manufactured by Atabay, Turkey.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAVICOVIR 200 mg Film Tablet
Description: FAVICOVIR 200 MG FT is containing 200 mg favipiravir manufactured by Atabay, Turkey.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVIGAN 200 mg Film Tablets
Description: AVIGAN 200 mg FT is containing 200 mg favipiravir manufactured by Toyama, Japan.
Study: NCT01822327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: CRA plus Vouchers contingent on drug abstinence with values the same across all patients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: CRA plus Vouchers contingent on cocaine abstinence with more severe patients receiving greater value vouchers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: CRA plus Vouchers earned independent of cocaine use
Study: NCT00892866

Intervention type: OTHER
Group type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: OTHER
Group type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01743144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
Study: NCT03983239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Fedratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Fedratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin
Study: NCT02448186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESTEEM
Description: 10-session cognitive behavioral treatment
Study: NCT01632917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101 - U.S.
Description: US ATX-101, 10 mg/mL, one dosing session in the submental area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101 - EU
Description: EU ATX-101, 10 mg/mL, one dosing session in the submental area
Study: NCT03793556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GERDOFF® + Omeprazole
Description: GERDOFF® Hyaluronic acid + chondroitin sulphate + hydroxide aluminium Melt-in-mouth tablet 1100 mg + Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole, 2 capsules 20 mg, once a day before breakfast
Study: NCT04406194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVIGAN 200 mg Film Tablets
Description: AVIGAN 200 mg FT is containing 200 mg favipiravir manufactured by Toyama, Japan.
Study: NCT02846233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP1 receptor agonist
Description: Albiglutide or Dulaglutide will be added to a basal insulin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basal insulin
Description: The participant will continue with the basal insulin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: Empagliflozin will be added to a basal insulin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The participant will continue with metformin.
Study: NCT03983239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Efavirenz

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Efavirenz
Study: NCT01842347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbiota
Study: NCT03441984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: DTG and 3TC (Adult), administered as a, single dose, Single dose, 1 tablet DTG (50 mg) and~1 tablet 3TC (300 mg), orally as direct-to-mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: DTG and 3TC (Adult), administered as a, single dose, Single dose, 1 tablet DTG (50 mg) and~1 tablet 3TC (300 mg), orally as direct-to-mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: DTG and 3TC (Adult), administered as a, single dose, Single dose, 1 tablet DTG (50 mg) and~1 tablet 3TC (300 mg), orally as direct-to-mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: DTG and 3TC (Adult), administered as a, single dose, Single dose, 1 tablet DTG (50 mg) and~1 tablet 3TC (300 mg), orally as direct-to-mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: DTG and 3TC (Adult), administered as a, single dose, Single dose, 1 tablet DTG (50 mg) and~1 tablet 3TC (300 mg), orally as direct-to-mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: DTG and 3TC (Adult), administered as a, single dose, Single dose, 1 tablet DTG (50 mg) and~1 tablet 3TC (300 mg), orally as direct-to-mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as 10 dispersible tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as 10 dispersible tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as 10 dispersible tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as 10 dispersible tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as 10 dispersible tablets.
Study: NCT04519567

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTI-1601
Description: CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT02840240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil
Description: 600 mg BID 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg BID 3 days post-operative

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 600 mg BID taken 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg 3 days post-operative
Study: NCT03207893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GEM lifestyle modification & continuous glucose monitoring
Description: Four treatment sessions of GEM lifestyle modification in 3 months and continuous glucose monitoring during the first 14 days of each of the 3 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Care
Description: Subject's current t2d treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Subject's current t2d treatment
Study: NCT02207465

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study: NCT03441984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as direct-to-mouth.
Study: NCT02207465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Dose varies within subtrial 1 to determine maximum dose. All patients in subtrial 2 receive 125mg Abraxane
Study: NCT03770611

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: The probiotic supplement is composed of the following bacterial strains: Bacillus coagulans, Bacillus subtilis, Bifidobacterium (B) bifidum, B. breve, B. longum, Lactobacillus (L) acidophilus, L. brevis, L. casei, L. helveticus, L. Paracasei, L plantarum, L. rhamnosus, L. salivarus, Lactococcus lactis, Pediococcus acidilactici, Pediococcus parvulus, Weisella confusa, Weisella paramesenteroides

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic
Description: The prebiotic fiber is Agave inulin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Symbiotic
Description: The supplement is a combination of the probiotic product + the prebiotic fiber
Study: NCT03441984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as direct-to-mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as direct-to-mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as direct-to-mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as direct-to-mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as direct-to-mouth.
Study: NCT03645356

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed Appliances
Description: Using an MBT-prescription of metallic brackets, patients will be treated in the conventional way

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clear Aligners
Description: Using a sequence of clear aligners, patients will be give an aligner every two weeks until the completion of treatment
Study: NCT00082719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa
Description: In all arms, treatment begins at pre-operative visit and continues until cystoscopy.~Arm I: Low-dose interferon alfa subcutaneously (SC) twice daily. Arm II: Interferon alfa as in arm I at a higher dose. Arm III: Interferon alfa SC once daily. Arm IV: Interferon alfa as in arm III at a higher dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa
Description: In all arms, treatment begins at pre-operative visit and continues until cystoscopy.~Arm I: Low-dose interferon alfa subcutaneously (SC) twice daily. Arm II: Interferon alfa as in arm I at a higher dose. Arm III: Interferon alfa SC once daily. Arm IV: Interferon alfa as in arm III at a higher dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa
Description: In all arms, treatment begins at pre-operative visit and continues until cystoscopy.~Arm I: Low-dose interferon alfa subcutaneously (SC) twice daily. Arm II: Interferon alfa as in arm I at a higher dose. Arm III: Interferon alfa SC once daily. Arm IV: Interferon alfa as in arm III at a higher dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa
Description: In all arms, treatment begins at pre-operative visit and continues until cystoscopy.~Arm I: Low-dose interferon alfa subcutaneously (SC) twice daily. Arm II: Interferon alfa as in arm I at a higher dose. Arm III: Interferon alfa SC once daily. Arm IV: Interferon alfa as in arm III at a higher dose.
Study: NCT02469064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training
Description: Respiratory muscle training is done twice every day, with 3 series of 10 repetitions each, with a resting pause of two minutes between series (during resting time, patient is connected to mechanical ventilation again). We adjust initial load for respiratory muscle training as 50% of MIP. At the end of every training session, we assess dyspnea (perceived effort) using Modified Borg Scale (23). Four physical therapists are in charge of Respiratory muscle training, these therapists work at ICU and have experience with critically ill patients.
Study: NCT03770611

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The supplement is a combination of probiotic placebo and prebiotic fiber placebo. Placebo will consist on maltodextrin for both cases.
Study: NCT00860496

Intervention type: DRUG
Group type: OTHER
Intervention: CP- 690,550 and Tacrolimus
Description: 10 mg, single dose of CP-690,550 on Day 1 5 mg, every 12 hours of Tacrolimus on Days 1-8 10 mg, single dose of CP-690,550 on Day 8
Study: NCT02207465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Dose varies within subtrial 1 to determine maximum dose. All patients in subtrial 2 receive 125mg Abraxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Dose varies within subtrial 1 to determine maximum dose. All patients in subtrial 2 receive 125mg Abraxane
Study: NCT01815983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy review.
Description: Review of video recordings.
Study: NCT00860496

Intervention type: DRUG
Group type: OTHER
Intervention: CP- 690,550 and Cyclosporine
Description: 10 mg, single dose of CP-690,550 on Day 1 200 mg, every 12 hours of Cyclosporine on Days 1-6 10 mg, single dose of CP-690,550 on Day 6
Study: NCT01654861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Intravenous and oral Ascorbic Acid (Vitamin C)
Description: Weeks 1,2,3: IV Gemcitabine 1000 mg / m² over 30 minutes followed by HDIVC 1.2 g / kg: 1.2 g/kg over 90 minutes for a dose ≤90 g and over 120 minutes for a dose \>90g followed by 0.3 g / kg over 120 minutes; Week 4: no treatment.
Study: NCT03004196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Toothpaste
Description: G.D Probiotic Toothpaste bacteriocin Lactic Acid Bacteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dr. Reddy's Clohex
Description: 0.20% Chlorhexidine Mouthwash

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: No Probiotic toothpaste \& Chlorhexidine Mouthwash
Study: NCT00265122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: one 90 mg SC injection each week for 4 weeks (Weeks 0-3 during Intervention Period 1 or Weeks 8-11 during Intervention Period 2 for Population 1 or Weeks 0-3 during Intervention Period 1 for Population 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: one 90 mg SC injection each week for 4 weeks (Weeks 0-3 during Intervention Period 1 or Weeks 8-11 during Intervention Period 2 for Population 1 or Weeks 0-3 during Intervention Period 1 for Population 2)
Study: NCT03253458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocal Laser Endomicroscopy
Description: Transperineal confocal laser endomicroscopy or optical coherence tomography measurements. Probe will be placed guided by ultrasound, similar procedure as transperineal template guided mapping biopsies.
Study: NCT02469064

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Physical Therapy
Description: Control group receives Cardiopulmonary Physical Therapy every 6 hours, physical therapy and mechanical ventilation management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Physical Therapy
Description: Control group receives Cardiopulmonary Physical Therapy every 6 hours, physical therapy and mechanical ventilation management
Study: NCT04499976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isonicotinic Acid
Description: Drug: Isonicotinic Acid then misoprostol Drug: Isonicotinic Acid 300mg total dose 900 mg per day for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: placebo then misoprostol Drug: Placebo placebo for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion
Study: NCT02682407

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OMS721 (narsoplimab)
Description: Biological: OMS721 (narsoplimab)
Study: NCT02126358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin and/or Rosuvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemigliptin and/or Rosuvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemigliptin and/or Rosuvastatin
Study: NCT02725645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: loading conditions
Description: Different backpack loading conditions 0%, 10%, 15% and 20% allocated randomly
Study: NCT03065699

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DIALIVE Liver Dialysis Device
Description: ACLF patients will receive dialysis treatment for 8-12 hrs/day and on three to five consecutive days over a 10-day time period. Dialysis treatment is performed by using the DIALIVE device provided by YAQRIT Ltd.
Study: NCT04035954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The control group will continue the routine NDT: Neurodevelopmental Therapy-based physiotherapy program twice a week. The treatment group will participate in clinical pilates exercises for 2 hours / day for 1 hour / 8 weeks. They will also continue their weekly routine physiotherapy programs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: The control group will continue the routine NDT: Neurodevelopmental Therapy-based physiotherapy program twice a week. The treatment group will participate in clinical pilates exercises for 2 hours / day for 1 hour / 8 weeks. They will also continue their weekly routine physiotherapy programs.
Study: NCT02855840

Intervention type: OTHER
Intervention: completion of the quality of life questionnaire

Intervention type: OTHER
Intervention: completion of the quality of life questionnaire

Intervention type: OTHER
Intervention: completion of the quality of life questionnaire
Study: NCT02045355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fish intervention
Description: The intervention will compare fish intake with a correspondent amount of meat. The basis for the comparison will be the estimated protein intake from fish and meat and should be almost similar both from fish and from meat. To ensure compliance and to add more variety to the diet, different fish types will be included in the intervention group and different meat sources in the control group. The types of fish (and that of meat in the control diet) that will be used will be accurately documented and will be similar for all participants included.